Soleno Therapeutics’ first-quarter sales of Vykat XR, a treatment for the insatiable hunger in Prader-Willi syndrome, exceeded market forecasts with $31–33 million in net revenues. The launch marked a significant milestone as the first drug approved specifically for this rare genetic disease’s hyperphagia. Physician interest and reimbursement dynamics have been favorable, underpinning demand. To support the commercial rollout, Soleno also raised $200 million in a stock offering. Despite strong launch metrics, share prices experienced slight volatility amid concerns about near-term mergers and acquisitions.